---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106636"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:10:58.450782+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools Q2 revenue $21.8M, net loss improves; sells SomaLogic to Illumina for up to $425M

## Summary
- Q2 2025 continuing ops revenue $21.8M, down 3% YoY; net loss $17.7M vs $25.4M loss a year ago.
- Consumables revenue up 18% YoY to $10.5M; instruments down 26% to $5.2M; services down 8% to $6.1M.
- Adjusted EBITDA loss $16.1M vs $17.4M; targeting adjusted EBITDA breakeven in 2026.
- Announced sale of SomaLogic to Illumina for up to $425M cash plus royalties; expected close H1 2026.
- FY2025 revenue outlook: combined $165-175M; continuing ops $78-83M; cash $239.7M, expects ≥$550M post-close.

## SEC filing metadata
- accession: 0000950170-25-106636
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000095017025106636/0000950170-25-106636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000095017025106636/lab-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106636
- JSON: https://secwatch.observer/filing/0000950170-25-106636.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106636.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.